A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004

Study identifier:D7260C00010

ClinicalTrials.gov identifier:NCT06857695

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

An Open-Label Study to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5004 and Absolute Bioavailability of AZD5004 in Healthy Male Participants

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5004 film-coated tablet, [14C]AZD5004 Solution for Infusion, [14C]AZD5004 Oral Solution

Sex

Male

Estimated Enrollment

8

Study type

Interventional

Age

30 Years - 65 Years

Date

Study Start Date: 06 Mar 2025
Estimated Primary Completion Date: 21 Apr 2025
Estimated Study Completion Date: 21 Apr 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Quotient Sciences Limited

Inclusion and exclusion criteria